Resource id #3DrugId:2d00000053resource(4) of type (mysql result) Drug Search

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main   

Drug ID: 2d00000053

Drug Name: Bortezomib

Generic Names: Onbort (2mg) | Onbort (3.5mg) | Mibor (2mg) | Borviz (3.5 mg) | Borviz | Mibor (3.5mg) | Velcade

Category: Chemotherapy

Legal Status: Non Opioid Prescription only drug


Indication for Mother: Category D
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Recommended Dose: Adult: 1.3 mg/m2 as bolus on days 1, 4, 8 and 11 of a 21-day cycle, followed by a 10-day rest period (days 12-21).

Recommended In: This medication is an antineoplastic agent, prescribed for multiple myeloma and mantle cell lymphoma. It works by killing cancer cells.

Directions For Use: It comes as a solution for injection to be administered by a healthcare provider into the vein.

Storage: Store the medication as directed by your physician.

Dosage Forms: Intravenous Injection

Side Effects: Blood - Anemia, decrease in white blood cells and platelets.

Gastrointestinal - Nausea, diarrhea, constipation, vomiting, abdominal pain and indigestion.

Central Nervous System - Nerve disease, dizziness, headache, sleeplessness and tingling.

General - Fever, fatigue, weakness and swelling in the extremities.

Infections - Pneumonia and lung infection.

Musculoskeletal - Back pain, pain in extremities and joint pain.

Metabolic - Loss of appetite.

Skin - Rash and itching.

Respiratory - Cough and difficulty in breathing.

Heart - Low or high blood pressure.

In Case of Overdose: There is no known specific antidote for Bortezomib overdosage. In humans, fatal outcomes following the administration of more than twice the recommended therapeutic dose have been reported, which were associated with the acute onset of symptomatic hypotension and thrombocytopenia. In the event of an overdosage, the patient's vital signs should be monitored and appropriate supportive care given.

Avoid If: Caution should be exercised in patients with history of heart disease, infection, sugar, fainting, high cholesterol, high or low blood pressure, weakness, alcoholism, kidney or liver disease, any allergy, who are taking other medications, during pregnancy and breastfeeding.

It may cause dizziness, drowsiness, lightheadedness or blurred vision, do not drive a car or operate machinery and get up slowly from bed while taking this medication.

Drug Interaction: CYP3A4 Inhibitors

Monitor patients for signs of bortezomib toxicity and consider a bortezomib dose reduction if bortezomib must be given in combination with strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir).

CYP3A4 Inducers

Efficacy may be reduced when bortezomib is used in combination with strong CYP3A4 inducers; therefore, concomitant use of strong CYP3A4 inducers (rifampin) is not recommended in patients receiving bortezomib. St. John's Wort (Hypericum perforatum) may decrease bortezomib exposure unpredictably and should be avoided.


Co-administration of melphalan-prednisone increased the exposure of bortezomib by 17% in 21 patients.

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main